

Date of AGM and Closing Date for Director Nominations

Melbourne, Australia, 29 September 2023: Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, "Company", "GTG"), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to advise that the Company's Annual General Meeting (AGM) is to be held 22nd November 2023. Further details of the meeting will be provided to shareholders in a separate Notice of Annual General Meeting to be released in due course.

In accordance with ASX Listing Rule 3.13.1 and the Company's constitution, GTG advises that the closing date for director nominations is 12th October 2023.

-END-

Authorised for release by the board of directors of Genetic Technologies Limited.

Enquiries

Investor Relations

Adrian Mulcahy

Automic Markets

M: +61 438 630 411

E: adrian.mulcahy@automicgroup.com.au

About Genetic Technologies Limited

Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GTG offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products. For more information, please visit www.genotype.com